1887

Journal of Medical Microbiology logo

Volume 72, Issue 6

Correlation analysis for alterations of intestinal flora in hepatocellular carcinoma patients: combinatorial detection of , , and may be a new method for HCC diagnosis Open Access

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumours in the world. Due to the characteristics of low early diagnosis rate, high malignancy and rapid progression, the majority of diagnosed patients are in the middle or late stage. Accumulating evidence reveals that intestinal flora imbalance will aggravate HCC by disturbing immune regulation, especially interleukin expression. Therefore, intestinal flora-based methods have the potential to be new diagnostic or therapeutic methods for HCC.

Compositions of intestinal florae were different between HCC patients and healthy people. Further, intestinal florae may alleviate or aggravate HCCs.

To determine which intestinal florae and interleukin aggravate HCCs, we studied the differences in intestinal florae composition and interleukin (IL) indices between HCC patients and healthy people. A total of 64 HCC patients and 24 healthy people were recruited, and their fresh stool samples and serum samples were collected for 16S rRNA sequencing and metabolite index measurement.

Data showed that 484 operational taxonomic units (OTUs) and 476 OTUs were detected in the HCC and control groups, respectively. From the phylum level to the species level, 5, 6, 10, 15, 23 and 19 colonies showed differential abundance between the HCC group and healthy people. Moreover, interleukin-6 expression and interleukin-10 expression were significantly different between two groups. Of note, differences of , and at genus level and at species level in two groups were significantly related to IL-6 and IL-10.

The abundance of intestinal florae in the HCC group was different from the control group. Additionally, combinatorial detection of , and at genus level and at species level may be a new method for HCC diagnosis.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): hepatocellular carcinoma , interleukin , intestinal flora and metabolite
Funding
This study was supported by the:
  • Scientific Research Projects of Medical and Health Institutions of Longhua District, Shenzhen (Award 2020016)
    • Principle Award Recipient: XiaoxinJiang
© 2023 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001713
2023-06-20
2024-05-17
Loading full text...

Full text loading...

/deliver/fulltext/jmm/72/6/jmm001713.html?itemId=/content/journal/jmm/10.1099/jmm.0.001713&mimeType=html&fmt=ahah

References

  1. Sasso FC. HCC and molecular targeting therapies: back to the future. Biomedicines 2021; 9:1345 [View Article] [PubMed]
     [Google Scholar]
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68:7–30 [View Article] [PubMed]
     [Google Scholar]
  3. Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med 2020; 52:1898–1907 [View Article] [PubMed]
     [Google Scholar]
  4. Sun H-C, Zhu X-D. Downstaging conversion therapy in patients with initially unresectable advanced hepatocellular carcinoma: an overview. Front Oncol 2021; 11:772195 [View Article] [PubMed]
     [Google Scholar]
  5. Chu P-Y, Chan S-H. Cure the incurable? Recent breakthroughs in immune checkpoint blockade for hepatocellular carcinoma. Cancers 2021; 13:5295 [View Article] [PubMed]
     [Google Scholar]
  6. Zhuo Y, Chen Q, Chhatwal J. Changing epidemiology of hepatocellular carcinoma and role of surveillance. In Hoshida Y. eds Hepatocellular Carcinoma: Translational Precision Medicine Approaches [Internet] Cham (CH): Humana Press; 2019 [View Article]
     [Google Scholar]
  7. Coker OO. Non-bacteria microbiome (virus, fungi, and archaea) in gastrointestinal cancer. J Gastroenterol Hepatol 2022; 37:256–262 [View Article] [PubMed]
     [Google Scholar]
  8. Vuong HE, Yano JM, Fung TC, Hsiao EY. The microbiome and host behavior. Annu Rev Neurosci 2017; 40:21–49 [View Article] [PubMed]
     [Google Scholar]
  9. Arumugam M, Raes J, Pelletier E et al. Enterotypes of the human gut microbiome. Nature 2011; 473:174–180 [View Article] [PubMed]
     [Google Scholar]
  10. Yılmaz İ, Dolar ME, Özpınar H. Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turk J Gastroenterol 2019; 30:242–253 [View Article] [PubMed]
     [Google Scholar]
  11. Mardinoglu A, Shoaie S, Bergentall M et al. The gut microbiota modulates host amino acid and glutathione metabolism in mice. Mol Syst Biol 2015; 11:834 [View Article] [PubMed]
     [Google Scholar]
  12. Zhang N, Gou Y, Liang S, Chen N, Liu Y et al. Dysbiosis of gut microbiota promotes hepatocellular carcinoma progression by regulating the immune response. J Immunol Res 2021; 2021:4973589 [View Article] [PubMed]
     [Google Scholar]
  13. Wu M, Bai J, Ma C et al. The role of gut microbiota in tumor immunotherapy. J Immunol Res 2021; 2021:5061570 [View Article] [PubMed]
     [Google Scholar]
  14. Zeng Y, Chen S, Fu Y et al. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. J Viral Hepat 2020; 27:143–155 [View Article] [PubMed]
     [Google Scholar]
  15. Gallon J, Coto-Llerena M, Ercan C et al. Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Mol Oncol 2022; 16:665–682 [View Article] [PubMed]
     [Google Scholar]
  16. Yu L-X, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 2017; 14:527–539 [View Article] [PubMed]
     [Google Scholar]
  17. Ruiz N, Davis RM, Kumar S. YhdP, TamB, and YdbH are redundant but essential for growth and lipid homeostasis of the gram-negative outer membrane. mBio 2021; 12:e0271421 [View Article] [PubMed]
     [Google Scholar]
  18. Yu L-X, Yan H-X, Liu Q et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 2010; 52:1322–1333 [View Article] [PubMed]
     [Google Scholar]
  19. Zhang H-L, Yu L-X, Yang W et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol 2012; 57:803–812 [View Article] [PubMed]
     [Google Scholar]
  20. Akkız H. The gut microbiome and hepatocellular carcinoma. J Gastrointest Cancer 2021; 52:1314–1319 [View Article] [PubMed]
     [Google Scholar]
  21. Wu L, Feng J, Li J et al. The gut microbiome-bile acid axis in hepatocarcinogenesis. Biomed Pharmacother 2021; 133:111036 [View Article] [PubMed]
     [Google Scholar]
  22. Schwabe RF, Greten TF. Gut microbiome in HCC - mechanisms, diagnosis and therapy. J Hepatol 2020; 72:230–238 [View Article] [PubMed]
     [Google Scholar]
  23. Zhou J, Sun H-C, Wang Z, Cong W-M, Wang J-H et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer 2018; 7:235–260 [View Article]
     [Google Scholar]
  24. Mirpuri J, Raetz M, Sturge CR et al. Proteobacteria-specific IgA regulates maturation of the intestinal microbiota. Gut Microbes 2014; 5:28–39 [View Article] [PubMed]
     [Google Scholar]
  25. Hu Y, Chen J, Xu Y et al. Alterations of gut microbiome and metabolite profiling in mice infected by Schistosoma japonicum. Front Immunol 2020; 11:569727 [View Article] [PubMed]
     [Google Scholar]
  26. Koliada A, Syzenko G, Moseiko V et al. Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC Microbiol 2017; 17:120 [View Article] [PubMed]
     [Google Scholar]
  27. Bor B, Bedree JK, Shi W, McLean JS, He X. Saccharibacteria (TM7) in the human oral microbiome. J Dent Res 2019; 98:500–509 [View Article] [PubMed]
     [Google Scholar]
  28. Costa M, Costa-Rodrigues J, Fernandes MH et al. Marine cyanobacteria compounds with anticancer properties: a review on the implication of apoptosis. Mar Drugs 2012; 10:2181–2207 [View Article] [PubMed]
     [Google Scholar]
  29. Yang H, Xuefeng Y, Jianhua X. Systematic review of the roles of interleukins in hepatocellular carcinoma. Clin Chim Acta 2020; 506:33–43 [View Article] [PubMed]
     [Google Scholar]
  30. Tanaka T, Narazaki M, Kishimoto T. Interleukin (IL-6) immunotherapy. Cold Spring Harb Perspect Biol 2018; 10:a028456 [View Article] [PubMed]
     [Google Scholar]
  31. Iwahasi S, Rui F, Morine Y et al. Hepatic stellate cells contribute to the tumor malignancy of hepatocellular carcinoma through the IL-6 pathway. Anticancer Res 2020; 40:743–749 [View Article] [PubMed]
     [Google Scholar]
  32. Zappacosta R, Rosini S, Aiello FB et al. Solitary plasmacytoma of the tonsillar site associated with actinomyces infection: the possible role of IL-6. J Biol Regul Homeost Agents 2012; 26:571–575 [PubMed]
     [Google Scholar]
  33. Nedelkopoulou N, Dhawan A, Xinias I et al. Interleukin 10: the critical role of a pleiotropic cytokine in food allergy. Allergol Immunopathol 2020; 48:401–408 [View Article] [PubMed]
     [Google Scholar]
  34. Xu Y, Tang X, Yang M et al. Interleukin 10 gene-modified bone marrow-derived dendritic cells attenuate liver fibrosis in mice by inducing regulatory T cells and inhibiting the TGF-β/Smad signaling pathway. Mediators Inflamm 2019; 2019:4652596 [View Article] [PubMed]
     [Google Scholar]
  35. Shimizu J, Kubota T, Takada E et al. Propionate-producing bacteria in the intestine may associate with skewed responses of IL10-producing regulatory T cells in patients with relapsing polychondritis. PLoS One 2018; 13:e0203657 [View Article] [PubMed]
     [Google Scholar]
  36. Zhuang L, Fulton RJ, Rettman P et al. Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma. Hepatol Int 2019; 13:75–83 [View Article] [PubMed]
     [Google Scholar]
  37. Zhou Z-F, Peng F, Li J-Y. Intratumoral IL-12 gene therapy inhibits tumor growth in a HCC-Hu-PBL-NOD/SCID murine model. Onco Targets Ther 2019; 12:7773–7784 [View Article] [PubMed]
     [Google Scholar]
  38. Zhuang P, Li H, Jia W et al. Eicosapentaenoic and docosahexaenoic acids attenuate hyperglycemia through the microbiome-gut-organs axis in db/db mice. Microbiome 2021; 9:185 [View Article] [PubMed]
     [Google Scholar]
  39. Keshavarzian A, Green SJ, Engen PA et al. Colonic bacterial composition in Parkinson’s disease. Mov Disord 2015; 30:1351–1360 [View Article] [PubMed]
     [Google Scholar]
  40. Caselli E, Soffritti I, D’Accolti M et al. Atopobium vaginae and Porphyromonas somerae induce proinflammatory cytokines expression in endometrial cells: a possible implication for endometrial cancer?. Cancer Manag Res 2019; 11:8571–8575 [View Article] [PubMed]
     [Google Scholar]
  41. Cobo F, Pérez-Carrasco V, García-Salcedo JA. Bacteremia caused by Veillonella dispar in an oncological patient. Anaerobe 2020; 66:102285 [View Article] [PubMed]
     [Google Scholar]
  42. Jang HJ, Choi JY, Kim K, Yong SH, Kim YW et al. Relationship of the lung microbiome with PD-L1 expression and immunotherapy response in lung cancer. Respir Res 2021; 22:322 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001713
Loading
Correlation analysis for alterations of intestinal flora in hepatocellular carcinoma patients: combinatorial detection of Coriobacterium, Atopobium, Coprococcus and Veillonella dispar may be a new method for HCC diagnosis
J. Med. Microbiol. 72, 001713 (2023); https://doi.org/10.1099/jmm.0.001713
/content/journal/jmm/10.1099/jmm.0.001713
/content/journal/jmm/10.1099/jmm.0.001713
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error